--- title: "HAEMONETICS CORP (HAE) stock: news and investor profile" url: "https://aibio.space/companies/haemonetics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "HAEMONETICS CORP (NYSE: HAE), United States. Listing facts, related biotech companies and news on aibio.space." --- HAE HAEMONETICS CORP NYSE · United States # HAEMONETICS CORP (HAE) news HAEMONETICS CORP is a public biotech or pharmaceutical company listed on NYSE under the ticker HAE, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. ## Latest HAEMONETICS CORP news We have not published a story on HAEMONETICS CORP yet. When there is news, it will appear here. ## HAEMONETICS CORP at a glance - **Ticker**: HAE - **Listing**: NYSE - **Country**: United States - **Cash, Jun 27, 2026**: $223.4 million ### Related companies - [NovoCure](https://aibio.space/companies/novocure/) NASDAQ: NVCR - [ORGANIGRAM GLOBAL INC.](https://aibio.space/companies/organigram-global/) NASDAQ: OGI - [Inogen](https://aibio.space/companies/inogen/) NASDAQ: INGN - [ALCON INC](https://aibio.space/companies/alcon/) NYSE: ALC - [IDEXX LABORATORIES INC /DE](https://aibio.space/companies/idexx-laboratories-de/) NASDAQ: IDXX - [BioXcel Therapeutics](https://aibio.space/companies/bioxcel-therapeutics-btaiq/) OTC: BTAIQ - [Asep Medical Holdings](https://aibio.space/companies/asep-medical/) OTC: SEPSF - [Renalytix](https://aibio.space/companies/renalytix/) OTC: RNLXY ### Also on NYSE - [Neuraxis, INC](https://aibio.space/companies/neuraxis/) NRXS - [QUEST DIAGNOSTICS INC](https://aibio.space/companies/quest-diagnostics/) DGX - [Cadre Holdings](https://aibio.space/companies/cadre/) CDRE - [GLOBUS MEDICAL INC](https://aibio.space/companies/globus-medical/) GMED - [Trulieve Cannabis](https://aibio.space/companies/trulieve-cannabis/) TRLV - [Perrigo Company](https://aibio.space/companies/perrigo/) PRGO ## What HAEMONETICS CORP does Haemonetics Corporation is a global medical technology company with three reportable segments: Plasma, Blood Center and Hospital. Its Plasma business offers automated plasma collection systems, donor management software and supporting software solutions for dedicated source plasma collection centers. Its NexSys PCS plasmapheresis collection system includes bi-directional connectivity to the NexLynk DMS donor management system. The NexSys PCS with YES technology is described as enabling increases in plasma yield per collection of an additional 18-26 mL per donation, on average. The Blood Center business supplies apheresis collection devices for blood collectors such as the American Red Cross. The Hospital segment comprises Interventional Technologies, including Vascular Closure, Sensor-Guided Technologies and Esophageal Protection, and Blood Management Technologies, including Hemostasis Management, Cell Salvage and Transfusion Management. The Plasma segment serves the market for plasma processed into pharmaceuticals, while the Blood Center segment serves the market for transfusion plasma. | Product or program | What it is | Stage | |---|---|---| | NexSys PCS | Automated plasmapheresis collection system for source plasma | FDA 510(k) clearance | | NexLynk DMS | Donor management system for plasma collection centers | | | Donor360 | Donor management tools for plasma centers | | Summarised from the company's [10-K filed May 20, 2026](https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/hae-20260328.htm). ## HAEMONETICS CORP annual financials | Line | FY ended Mar 28, 2026 | FY ended Mar 29, 2025 | |---|---|---| | Research and development | [$59.8 million](https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/) | [$62.7 million](https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/) | | Net income (loss) | [$97.3 million](https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/) | [$167.7 million](https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/) | | Cash from operations | [$293.2 million](https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/) | [$181.7 million](https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/) | | Cash and equivalents | [$245.4 million](https://www.sec.gov/Archives/edgar/data/313143/000031314326000120/) | [$306.8 million](https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/) | Latest balance sheet, Jun 27, 2026 (10-Q): cash and equivalents $223.4 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about HAEMONETICS CORP What is the ticker symbol of HAEMONETICS CORP? HAEMONETICS CORP trades under the ticker HAE on NYSE. Where is HAEMONETICS CORP listed? HAEMONETICS CORP is listed on NYSE. Which country or territory is HAEMONETICS CORP listed under? Our directory records HAEMONETICS CORP under United States. Does aibio.space cover HAEMONETICS CORP? aibio.space lists HAEMONETICS CORP among 2,820 public biotech companies and publishes its news here as stories appear. What does HAEMONETICS CORP develop? Haemonetics Corporation is a global medical technology company with three reportable segments: Plasma, Blood Center and Hospital. Its Plasma business offers automated plasma collection systems, donor management software and supporting software solutions for dedicated source plasma collection centers. What is NexSys PCS from HAEMONETICS CORP? NexSys PCS: Automated plasmapheresis collection system for source plasma Stage: FDA 510(k) clearance. What is NexLynk DMS from HAEMONETICS CORP? NexLynk DMS: Donor management system for plasma collection centers Is HAEMONETICS CORP profitable? HAEMONETICS CORP reported net income of $97.3 million for the fiscal year ended Mar 28, 2026, and generated $293.2 million of cash from operations, per its annual report to the SEC. How much does HAEMONETICS CORP spend on research and development? $59.8 million in the fiscal year ended Mar 28, 2026, per its annual report. How much cash does HAEMONETICS CORP have? $223.4 million in cash at Jun 27, 2026, per its 10-Q. ## Investor discussion: HAEMONETICS CORP Members talk about HAEMONETICS CORP (HAE). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at HAEMONETICS CORP, newest first. Each line links the filing it comes from. 1. 2026-05-20 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/hae-20260328.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NYSE:HAE on TradingView](https://www.tradingview.com/symbols/NYSE-HAE/). ## Listing details HAEMONETICS CORP is a public biotech or pharmaceutical company listed on NYSE under the ticker HAE, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: HAEMONETICS CORP - **Ticker**: HAE - **Listing**: NYSE - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/haemonetics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "HAEMONETICS CORP (HAE) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/haemonetics/